Setara launches with $90 million to develop Actio’s retained drug pipeline
Formed after Jazz acquired Actio, Setara will advance a TRPV4 inhibitor for a rare inherited nerve disease and overactive bladder.
An acquisition does not always take every drug programme with it. Setara Biosciences has emerged with $90 million to develop the pipeline retained after Jazz Pharmaceuticals acquired Actio Biosciences.
What happened
Setara completed its Series A on 30 October. Backers include Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital and Regeneron Ventures, with Jazz also becoming a shareholder through the Actio transaction.
Its lead programme, STAR-0871, is a small-molecule inhibitor of TRPV4, an ion channel involved in cellular signalling. Setara plans to develop it for Charcot-Marie-Tooth disease type 2C, a rare inherited nerve disorder, and overactive bladder, alongside earlier discovery programmes.
Why it matters
The company is pursuing a familiar precision-medicine strategy: understand a biological mechanism in a genetically defined disease, then investigate whether it can help a broader patient population.
The two proposed uses offer different development paths, but neither establishes that the treatment will work in patients.
The bigger picture
The financing gives the retained programmes their own company and development budget. Progress now depends on clinical evidence: whether blocking TRPV4 produces a useful benefit at a tolerable dose. The $90 million is financing for Setara, separate from the acquisition’s value.